Skip to main content

Zacks Analyst Blog Highlights: The Hain Celestial Group, Inc., H.J. Heinz Co., Harmony Gold Mining Company Ltd., AMAG Pharmaceuticals Inc. and Overseas Shipholding Group, Inc.

Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: The Hain Celestial Group, Inc. (Nasdaq: HAIN), H.J. Heinz Co. (NYSE: HNZ), Harmony Gold Mining Company Limited (NYSE: HMY), AMAG Pharmaceuticals Inc. (Nasdaq: AMAG) and Overseas Shipholding Group, Inc. (NYSE: OSG).

Get the most recent insight from Zacks Equity Research with the free Profit from the Pros newsletter: http://at.zacks.com/?id=4579

Here are highlights from Tuesdays Analyst Blog:

Hain Celestial Otherworldly

Hain Celestial Group (Nasdaq: HAIN) is the nation's largest manufacturer and marketer of natural food products, one of the fastest growing segments in the food industry. Management's acquisition activity has expanded the company's geographical presence and provided opportunities to cross-sell products.

Also, management is focused on improving profitability through new product introductions, cost cutting programs, another SKU [stock keeping units] Rationalization Program, and new co-packing arrangements. The improvement of performance metrics improved with the adoption of Heinz's (NYSE: HNZ) Operating Free Cash Flow and Cash Conversion Cycle model.

Harmony Gold Priced in Sync

South Africas Harmony Gold Mining Company Limited (NYSE: HMY) conducts underground and surface gold mining. It is also engaged in related activities such as exploration, processing, smelting and refining.

On October 31, 2008, Harmony Gold Mining Company Limited reported results for the first quarter of fiscal 2009 ended September 30, 2008. In the reported quarter, the company reported earnings from continuing operations of $0.012 (R0.117) per diluted share compared to net loss of $0.014 (R0.133) in the first quarter of fiscal 2008.

Amag Pharma a Magnificent Buy

AMAG Pharmaceuticals Inc. (Nasdaq: AMAG) develops superparamagnetic iron oxide nanoparticles for use in pharmaceutical products. The company's focus is on developing IV iron replacement therapy for anemia in chronic kidney disease and an imaging agent to aid in diagnosis.

The company filed the NDA [new drug application] for its lead drug, Ferumoxytol, in December 2007, and we expect the FDA approval to come in late 2008 or early 2009. Clinical data in over 1,700 patients indicate an excellent safety profile for the drug, with lower incidents of heart problems.

Overseas Shipholding Target Cut

Overseas Shipholding Group, Inc. (NYSE: OSG) is the second largest publicly listed oil tanker owner in the world as measured by number of vessels.

We are maintaining our Hold recommendation on Overseas Shipholding Group, but cutting our target price to $40. OSG reported third quarter diluted EPS of $4.84, well above consensus of $3.60 and our $3.10 estimate, primarily due to stronger-than-expected revenue growth from higher spot tanker rates and increased revenue days.

Want more from Zacks Equity Research? Subscribe to the free Profit from the Pros newsletter: http://at.zacks.com/?id=2649.

About Zacks Equity Research

Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.

Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.

Zacks "Profit from the Pros" e-mail newsletter provides highlights of the latest analysis from Zacks Equity Research. Subscribe to this free newsletter today: http://at.zacks.com/?id=2677

About Zacks

Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978 by Leonard Zacks. As a PhD in mathematics Len knew he could find patterns in stock market data that would lead to superior investment results. Amongst his many accomplishments was the formation of his proprietary stock picking system; the Zacks Rank, which continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros. In short, it's your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit from the Pros at http://at.zacks.com/?id=4580.

Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.

Disclaimer: Past performance does not guarantee future results. Investors should always research companies and securities before making any investments. Nothing herein should be construed as an offer or solicitation to buy or sell any security.

Contacts:

Zacks.com
Mark Vickery
Web Content Editor
312-265-9380
Visit: www.zacks.com

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.